The cell line Pr8/22 has been derived from P388, a methylcholanthrene-induced lymphoid neoplasm originating in DBA/2 mouse and converted to ascitic form in the first mouse transfer. Pr8/22 is resistant to daunorubicin and is multi drug resistant (MDR). Cells should be treated with the drug at least once a month and before freezing, however after resuscitating daunorubicin should not be added until the first passage. It is advisable to keep a backup culture which is not drug-challenged.
| Inventor | Institute |
|---|---|
| Timothy Ward | Cancer Research UK Manchester Institute |
| SKU: | 153248 |
|---|---|
| Product description: | The cell line Pr8/22 also known as P388 Pr8/22 has been derived from P388 (an immortal murine acute leukaemia cell line). Pr8/22 is resistant to daunorubicin (anthracycline antibiotic) and is multi drug resistant (MDR). Cells should be treated with the drug at least once a month and before freezing, however after resuscitating daunorubicin should not be added until the first passage. It is advisable to keep a backup culture which is not drug-challenged. Pr8/22 proves valuable in studying mechanisms underlying anthracycline antibiotic resistance and for making predictive assessments of resistance patterns. |
| Alternate name: | Pr8/22; PR8/22; P388R |
| Conditional: | No |
| Production details: | The cell line Pr8/22 has been derived from P388, a methylcholanthrene-induced lymphoid neoplasm. |
| Cellosaurus ID: | CVCL_4276 |
| Parental cell line: | P388 |
| Disease: | Cancer |
| Cat. #: | 153248 |
|---|---|
| Provenance and Ownership: | The Pr8/22 Cell Line is owned by Cancer Research UK. CancerTools supplies the Pr8/22 Cell Line under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing Pr8/22 Cell Line directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Research Fields: | Cancer; Drug development; Genetics |
| Organism: | Mouse |
| Tissue: | Lymphatic Tissue |
| Model: | Tumour line |
| Growth properties: | Suspension |
| Cancer Types In Detail: | Drug resistant |
| Format: | Frozen |
|---|---|
| Shipping conditions: | Dry ice |
| Growth medium: | Sub-culture routine: Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37°C. It is recommended to culture the cells without drug upon resuscitation until the first passage.Culture Medium: RPMI 1640 + 2mM Glutamine + 10% Horse Serum (HS); treat once a month with 0.1µM Daunorubicin. |
| Subculture routine: | Cells should be treated with the drug at least once a month and before freezing, however after resuscitating daunorubicin should not be added until the first passage. It is advisable to keep a backup culture which is not drug-challenged. |
| References: |
McGown et al. 1983. Cancer Chemother Pharmacol. 11(2):113-6. PMID: 6627597. Comparative studies of the uptake of daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and biochemical extraction procedures. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.